FENC
FENNEC PHARMACEUTICALS INC.
$9.00
+1.69%
$310.9M
No data for this timeframe.
Vol
Market Cap$310.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders36 funds
Inst. Value$22.8M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 5S
Insider Net $-$371.7K
SEC Reports9
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. A1·CIK 0001211583·Prev Close $8.85
Recent Activity
Jun 10, 2026
earnings
Fennec Announces Results of Annual Meeting
<p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmace
Jun 10, 2026
Insider
RALLIS CHRIS A was granted 20,000 shares
Director @ $8.70 ($174.0K)
Jun 10, 2026
Insider
Islam Khalid was granted 25,000 shares
Director @ $8.70 ($217.5K)
Jun 10, 2026
Insider
Cook Jodi A was granted 20,000 shares
Director @ $8.70 ($174.0K)
May 22, 2026
SEC
Fennec Pharmaceuticals announced that four independently led studies on PEDMARK (sodium thiosulfate injection) will be p
8-K — Impact 4/10
May 18, 2026
SEC
Fennec Pharmaceuticals filed an 8-K reporting the grant of stock options to purchase 50,000 common shares to three new n
8-K — Impact 2/10
May 14, 2026
SEC
Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 per diluted share, ver
PRESS-RELEASE — Impact 6/10
Inst.
Nuveen, LLC — DOUBLED
60,948 shares ($374.8K)
Price Targets
$15.67
+74.1% upside
Strong Buy
Current $9.00
Low $13.00
Median $16.00
High $18.00
6 analysts
$13.00
$18.00
Analyst Ratings
4Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 16, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Jan 9, 2026 | Piper Sandler | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.02 ▲ +288.5% | $0.00 — $0.05 | 119% YoY | 5 |
| Next Q | $0.11 ▲ +72.3% | $0.06 — $0.17 | 660% YoY | 5 |
| Current FY | $0.30 ▲ +79.4% | $0.18 — $0.47 | 205% YoY | 5 |
| Next FY | $0.89 ▼ -0.9% | $0.55 — $1.47 | 201% YoY | 5 |
Latest Reports
NEUTRAL
8-K
4/10
Fennec Pharmaceuticals announced that four independently led studies on PEDMARK (sodium thiosulfate injection) will be p
May 22, 2026
NEUTRAL
8-K
2/10
Fennec Pharmaceuticals filed an 8-K reporting the grant of stock options to purchase 50,000 common shares to three new n
May 18, 2026
NEUTRAL
Press
4/10
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study at the University of Arizo
Apr 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $8.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.5M | — |
| STATE STREET CORP | $2.2M | — |
| MORGAN STANLEY | $1.3M | DOUBLED |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | RALLIS CHRIS | A | $174.0K |
| Jun 10, 2026 | Islam Khalid | A | $217.5K |
| Jun 10, 2026 | Cook Jodi | A | $174.0K |
| Jun 10, 2026 | Brughera Marco | A | $174.0K |
| Jun 1, 2026 | Raykov Rosty | M | $38.2K |
36 institutional holders with $22.8M total value (3,722,597 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,368,176 | $8.4M | 36.9% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 897,144 | $5.5M | 24.2% | — |
| 3 | STATE STREET CORP | 359,055 | $2.2M | 9.7% | — |
| 4 | MORGAN STANLEY | 211,108 | $1.3M | 5.7% | DOUBLED +133.3% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 168,473 | $1.0M | 4.5% | — |
| 6 | CITADEL ADVISORS LLC | 153,610 | $944.7K | 4.1% | DOUBLED +129.8% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 63,537 | $390.8K | 1.7% | — |
| 8 | Nuveen, LLC | 60,948 | $374.8K | 1.6% | DOUBLED +134.4% |
| 9 | GOLDMAN SACHS GROUP INC | 55,664 | $342.3K | 1.5% | — |
| 10 | Trexquant Investment LP | 51,869 | $319.0K | 1.4% | — |
| 11 | STATE OF WISCONSIN INVESTMENT BOARD | 43,500 | $267.5K | 1.2% | ADD +58.9% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 38,724 | $238.2K | 1.0% | — |
| 13 | RHUMBLINE ADVISERS | 31,298 | $192.5K | 0.8% | — |
| 14 | BANK OF AMERICA CORP /DE/ | 26,405 | $162.4K | 0.7% | ADD +67.6% |
| 15 | JONES FINANCIAL COMPANIES LLLP | 24,952 | $147.5K | 0.6% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 22,400 | $137.8K | 0.6% | — |
| 17 | DEUTSCHE BANK AG\ | 21,202 | $130.4K | 0.6% | — |
| 18 | HighTower Advisors, LLC | 14,960 | $92.0K | 0.4% | — |
| 19 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 13,621 | $83.8K | 0.4% | ADD +25.3% |
| 20 | MetLife Investment Management, LLC | 13,509 | $83.1K | 0.4% | ADD +35.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | DOUBLED | 26,006 | 60,948 | +134.4% | $374.8K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 10,873 | 13,621 | +25.3% | $83.8K | 2026-Q1 |
| FMR LLC | ADD | 2,423 | 4,254 | +75.6% | $26.2K | 2026-Q1 |
| CWM, LLC | ADD | 750 | 1,063 | +41.7% | $6.5K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 12,504 | 16,865 | +34.9% | $104.00 | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 32,100 | 51,000 | +58.9% | $392.7K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 17,015 | 26,159 | +53.7% | $201.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 13,443 | 22,533 | +67.6% | $173.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 10,600 | 20,000 | +88.7% | $154.0K | 2025-Q4 |
| MetLife Investment Management, LLC | ADD | 9,593 | 13,019 | +35.7% | $100.2K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 968 | 637 | -34.2% | $4.9K | 2025-Q4 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 186 | 97 | -47.8% | $747.00 | 2025-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 46,783 | 107,496 | +129.8% | $1.0M | 2025-Q3 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 23,200 | 32,100 | +38.4% | $300.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 19,157 | 13,443 | -29.8% | $125.8K | 2025-Q3 |
| MetLife Investment Management, LLC | TRIM | 15,208 | 9,593 | -36.9% | $89.8K | 2025-Q3 |
| Russell Investments Group, Ltd. | DOUBLED | 976 | 3,674 | +276.4% | $34.4K | 2025-Q3 |
| FEDERATED HERMES, INC. | DOUBLED | 789 | 2,916 | +269.6% | $27.3K | 2025-Q3 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 64 | 186 | +190.6% | $1.8K | 2025-Q3 |
| TD Waterhouse Canada Inc. | ADD | 18 | 29 | +61.1% | $231.00 | 2025-Q3 |
| MetLife Investment Management, LLC | ADD | 12,051 | 15,208 | +26.2% | $126.2K | 2025-Q2 |
| UBS Group AG | TRIM | 26,254 | 13,024 | -50.4% | $108.1K | 2025-Q2 |
| Legal & General Group Plc | DOUBLED | 2,451 | 8,128 | +231.6% | $67.4K | 2025-Q2 |
| Russell Investments Group, Ltd. | DOUBLED | 449 | 976 | +117.4% | $8.1K | 2025-Q2 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 3 | 64 | +2033.3% | $531.00 | 2025-Q2 |
10 unique insiders with 50 transactions. Net insider value: -$371.7K ($0.00 bought, $371.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | RALLIS CHRIS A | Director | AWARD | 20,000 | $8.70 | $174.0K |
| Jun 10, 2026 | Islam Khalid | Director | AWARD | 25,000 | $8.70 | $217.5K |
| Jun 10, 2026 | Cook Jodi A | Director | AWARD | 20,000 | $8.70 | $174.0K |
| Jun 10, 2026 | Brughera Marco Maria | Director | AWARD | 20,000 | $8.70 | $174.0K |
| Jun 1, 2026 | Raykov Rosty | Director | EXERCISE | 15,597 | $2.45 | $38.2K |
| Jun 1, 2026 | Raykov Rosty | Director | SELL | 9,747 | $9.62 | $93.8K |
| May 31, 2026 | Raykov Rosty | Director | AWARD | 2,778 | — | — |
| May 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | AWARD | 1,703 | — | — |
| May 31, 2026 | Evans Terry L | Chief Commercial Officer | AWARD | 168 | — | — |
| May 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | AWARD | 168 | — | — |
| May 31, 2026 | Hackman Jeffrey S. | Chief Executive Officer | AWARD | 1,159 | — | — |
| May 31, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | AWARD | 156 | — | — |
| May 11, 2026 | RALLIS CHRIS A | Director | EXERCISE | 14,344 | $2.44 | $35.0K |
| May 11, 2026 | RALLIS CHRIS A | Director | SELL | 8,346 | $7.04 | $58.8K |
| May 1, 2026 | Raykov Rosty | Director | EXERCISE | 15,598 | $2.45 | $38.2K |
| May 1, 2026 | Raykov Rosty | Director | SELL | 10,781 | $6.47 | $69.8K |
| Apr 30, 2026 | Hackman Jeffrey S. | Chief Executive Officer | EXERCISE | 1,159 | — | — |
| Apr 30, 2026 | Evans Terry L | Chief Commercial Officer | EXERCISE | 168 | — | — |
| Apr 30, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | EXERCISE | 1,703 | — | — |
| Apr 30, 2026 | Sayad Pierre Sargis | Chief Medical Officer | EXERCISE | 168 | — | — |
| Apr 30, 2026 | Raykov Rosty | Director | EXERCISE | 2,778 | — | — |
| Apr 1, 2026 | Raykov Rosty | Director | SELL | 10,946 | $6.31 | $69.1K |
| Apr 1, 2026 | Raykov Rosty | Director | EXERCISE | 15,598 | $2.45 | $38.2K |
| Mar 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | EXERCISE | 18,456 | — | — |
| Mar 31, 2026 | Evans Terry L | Chief Commercial Officer | EXERCISE | 18,456 | — | — |
| Mar 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | AWARD | 120,000 | $5.77 | $692.4K |
| Mar 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | EXERCISE | 14,724 | — | — |
| Mar 31, 2026 | Raykov Rosty | Director | AWARD | 5,208 | — | — |
| Mar 31, 2026 | Evans Terry L | Chief Commercial Officer | AWARD | 120,000 | $5.77 | $692.4K |
| Mar 31, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | AWARD | 120,000 | $5.77 | $692.4K |
| Mar 31, 2026 | Evans Terry L | Chief Commercial Officer | EXERCISE | 171 | — | — |
| Mar 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | EXERCISE | 171 | — | — |
| Mar 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | AWARD | 120,000 | $5.77 | $692.4K |
| Mar 31, 2026 | Hackman Jeffrey S. | Chief Executive Officer | AWARD | 200,000 | $5.77 | $1.2M |
| Mar 31, 2026 | Hackman Jeffrey S. | Chief Executive Officer | EXERCISE | 16,695 | — | — |
| Mar 31, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | EXERCISE | 17,106 | — | — |
| Mar 28, 2026 | Hackman Jeffrey S. | Chief Executive Officer | EXERCISE | 13,943 | — | — |
| Mar 28, 2026 | Evans Terry L | Chief Commercial Officer | EXERCISE | 2,052 | — | — |
| Mar 28, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | EXERCISE | 1,901 | — | — |
| Mar 28, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | EXERCISE | 12,270 | — | — |
| Mar 28, 2026 | Sayad Pierre Sargis | Chief Medical Officer | EXERCISE | 2,052 | — | — |
| Mar 26, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | EXERCISE | 4,700 | $4.23 | $19.9K |
| Mar 26, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | EXERCISE | 13,072 | $5.10 | $66.7K |
| Mar 2, 2026 | Raykov Rosty | Director | EXERCISE | 15,598 | $2.45 | $38.2K |
| Feb 28, 2026 | Raykov Rosty | Director | AWARD | 5,208 | — | — |
| Feb 28, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | AWARD | 1,191 | — | — |
| Feb 2, 2026 | Raykov Rosty | Director | EXERCISE | 15,598 | $2.45 | $38.2K |
| Feb 2, 2026 | Raykov Rosty | Director | SELL | 10,349 | $7.76 | $80.3K |
| Jan 31, 2026 | Raykov Rosty | Director | AWARD | 5,208 | — | — |
| Jan 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | AWARD | 1,558 | — | — |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
4/10
Fennec Pharmaceuticals announced that four independently led studies on PEDMARK (sodium thiosulfate
May 22, 2026
NEUTRAL
8-K
2/10
Fennec Pharmaceuticals filed an 8-K reporting the grant of stock options to purchase 50,000 common s
May 18, 2026
BULLISH
PRESS-RELEASE
6/10
Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 pe
May 14, 2026
NEUTRAL
PRESS-RELEASE
2/10
Fennec Pharmaceuticals announced it will release Q1 2026 financial results on May 14, 2026. The pres
May 7, 2026
NEUTRAL
8-K
2/10
Director Rostislav Raykov will retire from the Board of Fennec Pharmaceuticals and not stand for re-
Apr 28, 2026
NEUTRAL
8-K
3/10
Fennec Pharmaceuticals announced that four clinical studies on PEDMARK were accepted for presentatio
Apr 22, 2026
NEUTRAL
8-K
4/10
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study by the
Apr 7, 2026
NEUTRAL
8-K
4/10
Fennec Pharmaceuticals announced a clinical research collaboration with Tampa General Hospital Cance
Mar 4, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their
Feb 28, 2026
NEUTRAL
4/10
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study at the
Apr 7, 2026
BULLISH
8/10
Fennec Pharmaceuticals reported strong financial and operational performance for FY 2025, with recor
Mar 24, 2026
NEUTRAL
3/10
Fennec Pharmaceuticals announced it will release its full year and fourth quarter 2025 financial res
Mar 18, 2026
NEUTRAL
4/10
Fennec Pharmaceuticals announced that Tampa General Hospital (TGH) Cancer Institute is initiating a
Mar 4, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 4 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.67 mean target
+74.1% upside
Strong Buy (1.33)
$13.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $9.00 |
| Target Low | $13.00 |
| Target Mean | $15.67 |
| Target Median | $16.00 |
| Target High | $18.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.02 | $0.00 | $0.05 | 119.2% | +288.5% | 0↑ 2↓ | $0.0B | 67.0% | 5 |
| Next Q 2026-09-30 |
$0.11 | $0.06 | $0.17 | 660.0% | +72.3% | 4↑ 1↓ | $0.0B | 47.6% | 5 |
| Current FY 2026-12-31 |
$0.30 | $0.18 | $0.47 | 204.7% | +79.4% | 4↑ 2↓ | $0.1B | 56.4% | 5 |
| Next FY 2027-12-31 |
$0.89 | $0.55 | $1.47 | 200.7% | -0.9% | 3↑ 3↓ | $0.1B | 43.9% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.022 | |
| 7d ago | $0.020 | +0.002 |
| 30d ago | $-0.012 | +0.034 |
| 60d ago | $0.043 | -0.021 |
| 90d ago | $0.106 | -0.084 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 16, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 9, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
earnings
Fennec Announces Results of Annual Meeting
<p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FR
May 21, 2026
routine
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
<p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><sup><em>®</em></sup><em> (so
May 18, 2026
other
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or t
May 14, 2026
earnings
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 14, 2026
earnings_calendar
FENC Q1 2026 Earnings Scheduled — 2026-05-14
May 11, 2026
earnings_calendar
FENC Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
<p align="justify">RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial
May 7, 2026
earnings_calendar
FENC Q1 2026 Earnings Scheduled — 2026-05-07
Apr 21, 2026
routine
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
<p align="center"><em>– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Last
Apr 7, 2026
fda
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
<p align="center"><em>~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK</em><sup><em>®</em></sup><em> in AYA & Adul
Mar 31, 2026
other
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or
Mar 24, 2026
earnings
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>~ Delivered Record Annual Revenue with Full-Year Net PEDMARK</em><sup><em>®</em></sup><em> Product Sales of $44.6 Million, Repre
Mar 24, 2026
earnings_calendar
FENC Q4 2025 Earnings After Market Close — 2026-03-24
Mar 18, 2026
earnings
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
<p align="justify">RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commerci
Mar 16, 2026
other
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
<p align="justify">RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty